{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:14:03Z","timestamp":1675988043106},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s00347-012-2780-z","type":"journal-article","created":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T18:12:40Z","timestamp":1363371160000},"page":"273-284","source":"Crossref","is-referenced-by-count":5,"title":["Morbus Beh\u00e7et \u2013 ophthalmologische und allgemeine Aspekte"],"prefix":"10.1007","volume":"110","author":[{"given":"U.","family":"Pleyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hazirolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Winterhalter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"St\u00fcbiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,17]]},"reference":[{"key":"2780_CR1","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, M\u00f6hle A et al (2010) Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease. Arthritis Rheum 62:2796\u20132805","journal-title":"Arthritis Rheum"},{"key":"2780_CR2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/bjo.86.5.521","volume":"86","author":"Toker","year":"2002","unstructured":"Toker E, Kazoko\u011flu H, Acar N (2002) High dose intravenous steroid therapy for severe posterior segment uveitis in Beh\u00e7et\u2019s disease. Br J Ophthalmol 86:521\u2013523","journal-title":"Br J Ophthalmol"},{"key":"2780_CR3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajo.2004.02.053","volume":"138","author":"Karacorlu","year":"2004","unstructured":"Karacorlu M, Mudun B, Ozdemir H et al (2004) Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Beh\u00e7et disease. Am J Ophthalmol 138:289\u2013291","journal-title":"Am J Ophthalmol"},{"key":"2780_CR4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ajo.2005.08.013","volume":"141","author":"Ohguro","year":"2006","unstructured":"Ohguro N, Yamanaka E, Otori Y et al (2006) Repeated intravitreal triamcinolone injections in Beh\u00e7et disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol 141:218\u2013220","journal-title":"Am J Ophthalmol"},{"key":"2780_CR5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","volume":"1","author":"Masuda","year":"1989","unstructured":"Masuda K, Nakajima A, Urayama A et al (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease. Lancet 1(8647):1093\u20131096","journal-title":"Lancet"},{"key":"2780_CR6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.1780280611","volume":"28","author":"Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC et al (1985) Effectiveness of cyclosporin therapy for Beh\u00e7et\u2019s disease. Arthritis Rheum 28:671\u2013679","journal-title":"Arthritis Rheum"},{"key":"2780_CR7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"K\u00f6tter","year":"2003","unstructured":"K\u00f6tter I, Zierhut M, Eckstein AK (2003) Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423\u2013431","journal-title":"Br J Ophthalmol"},{"key":"2780_CR8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1442-9071.2001.00445.x","volume":"29","author":"Kato","year":"2001","unstructured":"Kato Y, Numaga J, Kato S et al (2001) Central nervous system symptoms in a population of Beh\u00e7et\u2019s disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 29:335\u2013336","journal-title":"Clin Experiment Ophthalmol"},{"key":"2780_CR9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","volume":"25","author":"K\u00f6tter","year":"2006","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Batra M et al (2006) CNS involvement occurs more frequently in patients with Beh\u00e7et\u2019s disease under cyclosporin A (CSA) than under other medications \u2013 results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482\u2013486","journal-title":"Clin Rheumatol"},{"key":"2780_CR10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","volume":"123","author":"Murphy","year":"2005","unstructured":"Murphy CC, Greiner K, Plskova J et al (2005) Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 123:634\u2013641","journal-title":"Arch Ophthalmol"},{"key":"2780_CR11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1076\/ocii.6.2.101.4051","volume":"6","author":"Kilmartin","year":"1998","unstructured":"Kilmartin DJ, Forrester JV, Dick AD (1998) Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 6:101\u2013109","journal-title":"Ocul Immunol Inflamm"},{"key":"2780_CR12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0161-6420(99)90156-2","volume":"106","author":"Sloper","year":"1999","unstructured":"Sloper CM, Powell RJ, Dua HS (1999) Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106:723\u2013728","journal-title":"Ophthalmology"},{"key":"2780_CR13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N Engl J Med 322(5):281\u2013285","journal-title":"N Engl J Med"},{"key":"2780_CR14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3349\/ymj.1997.38.6.401","volume":"38","author":"Bang","year":"1997","unstructured":"Bang D (1997) Treatment of Beh\u00e7et\u2019s disease. Yonsei Med J 38:401\u2013410","journal-title":"Yonsei Med J"},{"key":"2780_CR15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/08830189709116844","volume":"14","author":"Mochizuki","year":"1997","unstructured":"Mochizuki M (1997) Immunotherapy for Beh\u00e7et\u2019s disease. Int Rev Immunol 14:49\u201366","journal-title":"Int Rev Immunol"},{"key":"2780_CR16","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","volume":"44","author":"Yurdakul","year":"2001","unstructured":"Yurdakul S, Mat C, T\u00fcz\u00fcn Y et al (2001) A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome. Arthritis Rheum 44:2686\u20132692","journal-title":"Arthritis Rheum"},{"key":"2780_CR17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000051781","volume":"203","author":"Adler","year":"2001","unstructured":"Adler YD, Mansmann U, Zouboulis CC (2001) Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Beh\u00e7et\u2019s disease. Dermatology 203:322\u2013324","journal-title":"Dermatology"},{"key":"2780_CR18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0002-9343(84)90753-8","volume":"76","author":"O","year":"1984","unstructured":"O\u2019Duffy JD, Robertson DM, Goldstein NP (1984) Chlorambucil in the treatment of uveitis and meningoencephalitis of Beh\u00e7et\u2019s disease. Am J Med 76:75\u201384","journal-title":"Am J Med"},{"key":"2780_CR19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","volume":"128","author":"Hamuryudan","year":"1998","unstructured":"Hamuryudan V, Mat C, Saip S et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized double-blind placebo-controlled trial. Ann Intern Med 128:443\u2013450","journal-title":"Ann Intern Med"},{"key":"2780_CR20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00347-010-2256-y","volume":"108","author":"Pleyer","year":"2011","unstructured":"Pleyer U, Mackensen F, Winterhalter S, St\u00fcbiger N (2011) Anti-TNF-Therapie bei Uveitis. Eine Standortbestimmung. Ophthalmologe 108:13\u201320","journal-title":"Ophthalmologe"},{"key":"2780_CR21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E et al (2011) Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61\u201370","journal-title":"Semin Arthritis Rheum"},{"key":"2780_CR22","doi-asserted-by":"crossref","unstructured":"Hazirolan D, St\u00fcbiger N, Pleyer U (2011) Light on the horizont: biologicals in Beh\u00e7et uveitis. Acta Ophthalmol, doi: 10.1111\/j.1755-3768.2011.02348.x","DOI":"10.1111\/j.1755-3768.2011.02348.x"},{"key":"2780_CR23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"Sfikakis","year":"2004","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A et al (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 140:404\u2013406","journal-title":"Ann Intern Med"},{"key":"2780_CR24","first-page":"1362","volume":"31","author":"Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, et al (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol 31:1362\u20131368","journal-title":"J Rheumatol"},{"key":"2780_CR25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","volume":"89","author":"Lindstedt","year":"2005","unstructured":"Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM (2005) Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89:533\u2013536","journal-title":"Br J Ophthalmol"},{"key":"2780_CR26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","volume":"51","author":"Accorinti","year":"2007","unstructured":"Accorinti M, Pirraglia MP, Paroli MP et al (2007) Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et\u2019s disease. Jpn J Ophthalmol 51:191\u2013196","journal-title":"Jpn J Ophthalmol"},{"key":"2780_CR27","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","volume":"1110","author":"Tognon","year":"2007","unstructured":"Tognon S, Graziani G, Marcolongo R (2007) Anti-TNF-alpha therapy in seven patients with Behcet\u2019s uveitis: advantages and controversial aspects. Ann N Y Acad Sci 1110:474\u2013484","journal-title":"Ann N Y Acad Sci"},{"key":"2780_CR28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","volume":"146","author":"Tabbara","year":"2008","unstructured":"Tabbara KF, Al-Hemidan AI (2008) Infliximab effects compared to conventional therapyin the management of retinal vasculitis in Beh\u00e7et disease. Am J Ophthalmol 146:845\u2013850.e1","journal-title":"Am J Ophthalmol"},{"key":"2780_CR29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H et al (2010) Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease. Br J Ophthalmol 94:284\u2013288","journal-title":"Br J Ophthalmol"},{"key":"2780_CR30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210401400515","volume":"14","author":"Giansanti","year":"2004","unstructured":"Giansanti F, Barbera ML, Virgili G (2004) Infliximab for the treatment of posterior uveitis with retinal neovascularization in Beh\u00e7et disease. Eur J Ophthalmol 14:445\u2013448","journal-title":"Eur J Ophthalmol"},{"key":"2780_CR31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","volume":"19","author":"Benitez-del-Castillo","year":"2005","unstructured":"Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E et al (2005) Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 19:841\u2013845","journal-title":"Eye"},{"key":"2780_CR32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/039463200902200235","volume":"22","author":"Cantarini","year":"2009","unstructured":"Cantarini L, Tinazzi I, Caramaschi P et al (2009) Safety and efficacy of entanercept in children with juvenile onset of Behcet\u2019s disease. Int J Immunopathol Pharmacol 22:551\u2013555","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2780_CR33","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","volume":"21","author":"Mustaq","year":"2007","unstructured":"Mustaq B, Saeed T, Situnayake RD et al (2007) Adalimumab for sight-threatening uveitis in Behcet\u2019s disease. Eye 21:824\u2013825","journal-title":"Eye"},{"key":"2780_CR34","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of Infliximab in the treatment of uveitis that is refractory to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet\u2019s disease. An open-label trial. Arthritis Rheum 52:2478\u20132484","journal-title":"Arthritis Rheum"},{"key":"2780_CR35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1157\/13083329","volume":"126","author":"Cobo-Ibanez","year":"2006","unstructured":"Cobo-Ibanez T, Munoz-Fernandez S, Hidalgo-Barrero V et al (2006) Medium long-term treatment with infliximab and methotrexate in posterior and\/or chronic uveitis refractory to conventional treatment. Med Clin 126:34\u201335","journal-title":"Med Clin"},{"key":"2780_CR36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","volume":"31","author":"Takase","year":"2011","unstructured":"Takase K, Ohno S, Ideguchi H et al (2011) Succesful switching to adalimumab in an infliximab-allergic patient with severe Behcet\u2019s disease related uveitis. Rheumatol Int 31:243\u2013245","journal-title":"Rheumatol Int"},{"key":"2780_CR37","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/02713683.2010.486520","volume":"35","author":"Kakkassery","year":"2010","unstructured":"Kakkassery V, Mergler S, Pleyer U (2010) Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 35:751\u2013756","journal-title":"Curr Eye Res"},{"key":"2780_CR38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"G\u00fcl","year":"2012","unstructured":"G\u00fcl A, Tugal-Tutkun I, Dinarello CA et al (2012) Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: an open-label pilot study. Ann Rheum Dis 71:563\u2013566","journal-title":"Ann Rheum Dis"},{"key":"2780_CR39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","volume":"27","author":"Deuter","year":"2008","unstructured":"Deuter CM, K\u00f6tter I, Wallace GR et al (2008) Beh\u00e7et\u2019s disease: ocular effects and treatment. Prog Retin Eye Res 27:111\u2013136","journal-title":"Prog Retin Eye Res"},{"key":"2780_CR40","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00347-012-2698-5","volume":"109","author":"Pleyer","year":"2012","unstructured":"Pleyer U, Hazirolan D, Winterhalter S, St\u00fcbiger N (2012) Morbus Beh\u00e7et \u2013 ophthalmologische und allgemeine Aspekte I. Ophthalmologe 109:1129\u20131143","journal-title":"Ophthalmologe"},{"key":"2780_CR41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M et al (2004) The use of interferon alpha in Beh\u00e7et disease: review of the literature. Semin Arthritis Rheum 33:320\u2013335","journal-title":"Semin Arthritis Rheum"},{"key":"2780_CR42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","volume":"146","author":"Gueudry","year":"2008","unstructured":"Gueudry J, Wechsler B, Terrada C et al (2008) Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet\u2019s disease. Am J Ophthalmol 146:837\u2013844","journal-title":"Am J Ophthalmol"},{"key":"2780_CR43","first-page":"896","volume":"35","author":"Krause","year":"2008","unstructured":"Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Beh\u00e7et\u2019s disease treated with interferon-alfa-2a. J Rheumatol 35:896\u2013903","journal-title":"J Rheumatol"},{"key":"2780_CR44","unstructured":"Yang DS, Galatowicz G, Calder VL et al (2009) Upregulation of Foxp3 expression by recombinant interferon-alpha therapy in Behcet\u2019s disease. ARVO, Poster No. 1535"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-012-2780-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-012-2780-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-012-2780-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T21:19:47Z","timestamp":1562793587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-012-2780-z"}},"subtitle":["Teil\u00a02: Therapie"],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["2780"],"URL":"https:\/\/doi.org\/10.1007\/s00347-012-2780-z","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}